VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$99.9M
1-Year Return
37.46%
This Quarter Return
+15.01%
1 Year Return
+37.46%
3 Year Return
+659.14%
5 Year Return
–
10 Year Return
–
AUM
$99.9M
AUM Growth
+$2.74M
(+2.8%)
Cap. Flow
-$2.31M
Cap. Flow
% of AUM
-2.32%
Top 10 Holdings %
Top 10 Hldgs %
70.22%
Holding
57
New
9
Increased
16
Reduced
5
Closed
7
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$4.87M |
| 2 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$4.86M |
| 3 |
Arvinas
ARVN
|
$3.68M |
| 4 |
Rezolute
RZLT
|
$1.56M |
| 5 |
Sutro Biopharma
STRO
|
$1.45M |
Top Sells
| 1 |
SLRN
ACELYRIN
SLRN
|
$8.32M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.19M |
| 3 |
Praxis Precision Medicines
PRAX
|
$1.5M |
| 4 |
Instil Bio
TIL
|
$1.2M |
| 5 |
Immunome
IMNM
|
$1.03M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Corbus Pharmaceuticals
CRBP
$123M
| $407K | 0.4% |
59,000
| – | – |
|
27
Kiora Pharmaceuticals
KPRX
$9.37M
| $352K | 0.35% |
122,223
| – | – |
|
28
Protagonist Therapeutics
PTGX
$3.71B
| $204K | 0.2% |
+3,700
| New | +$204K |
|
29
CytomX Therapeutics
CTMX
$346M
| $170K | 0.17% |
75,000
| – | – |
|
30
Nurix Therapeutics
NRIX
$697M
| $114K | 0.11% |
+10,000
| New | +$114K |
|
31
Geron
GERN
$880M
| $98.7K | 0.1% |
70,000
-585,000
| -89% | -$825K |
|
32
Wave Life Sciences
WVE
$1.3B
| $97.5K | 0.1% |
15,000
+2,000
| +15% | +$13K |
|
33
Larimar Therapeutics
LRMR
$331M
| $95.4K | 0.09% |
33,000
+5,000
| +18% | +$14.5K |
|
34
Gossamer Bio
GOSS
$571M
| $92.3K | 0.09% |
75,000
| – | – |
|
35
ProQR Therapeutics
PRQR
$252M
| $91.8K | 0.09% |
45,000
| – | – |
|
36
Ventyx Biosciences
VTYX
$185M
| $85.6K | 0.08% |
40,000
| – | – |
|
37
Erasca
ERAS
$420M
| $82.6K | 0.08% |
65,000
+15,000
| +30% | +$19.1K |
|
38
Alector
ALEC
$285M
| $77K | 0.08% |
55,000
| – | – |
|
39
Terns Pharmaceuticals
TERN
$618M
| $74.6K | 0.07% |
20,000
+3,000
| +18% | +$11.2K |
|
40
Design Therapeutics
DSGN
$348M
| $67.4K | 0.07% |
20,000
+6,000
| +43% | +$20.2K |
|
41
Context Therapeutics
CNTX
$74.3M
| $65.5K | 0.06% |
100,000
+10,000
| +11% | +$6.55K |
|
42
Ovid Therapeutics
OVID
$91.7M
| $52.8K | 0.05% |
160,000
+63,000
| +65% | +$20.8K |
|
43
Immix Biopharma
IMMX
$63.1M
| $51.8K | 0.05% |
+25,000
| New | +$51.8K |
|
44
VYNE Therapeutics
VYNE
$7.91M
| $49.5K | 0.05% |
+30,000
| New | +$49.5K |
|
45
Aclaris Therapeutics
ACRS
$224M
| $46.4K | 0.05% |
32,700
-2,300
| -7% | -$3.27K |
|
46
4D Molecular Therapeutics
FDMT
$309M
| $44.5K | 0.04% |
12,000
| – | – |
|
47
Pyxis Oncology
PYXS
$99.8M
| $44K | 0.04% |
+40,000
| New | +$44K |
|
48
PMV Pharmaceuticals
PMVP
$76.3M
| $37.1K | 0.04% |
35,000
| – | – |
|
49
NextCure
NXTC
$13.2M
| $20.7K | 0.02% |
3,750
+1,667
| +80% | +$9.2K |
|
|
ELEV
50
DELISTED
Elevation Oncology
ELEV
| – | – |
-45,000
| Closed | -$11.7K |
|